SALEKI-GERHARDT AZITA 4

4 · AbbVie Inc. · Filed Feb 20, 2026

Research Summary

AI-generated summary of this filing

Updated Feb 20, 2026

AbbVie (ABBV) EVP Azita Saleki‑Gerhardt Receives 57,123-Share Award

What Happened

Azita Saleki‑Gerhardt, Executive Vice President and Chief Operations Officer of AbbVie (ABBV), was credited with four performance-based awards (totaling 57,123 shares) on February 18, 2026. The reported entries show acquisitions at $0.00 per share (awards/grants), with one line reported as a derivative award. These shares were released upon certification of performance goal attainment and are scheduled to be issued to her on February 28, 2026.

Key Details

Transaction date: February 18, 2026; filing date: February 20, 2026 (two days later).
Award tranches reported: 17,041; 6,058; 7,074; 6,638; and 20,312 (derivative) — total 57,123 shares; reported acquisition price $0.00 (award).
Awards originate from prior grants: Feb 16, 2023 (performance share award tied to EPS and relative TSR), Feb 16, 2023 (performance‑vesting RSUs tied to relative ROE), Feb 15, 2024 (performance‑vesting RSUs tied to relative ROE), and Feb 13, 2025 (performance‑vesting RSUs tied to relative ROE). See footnotes F1–F4.
Shares will be issued on Feb 28, 2026 (per filing). The filing does not disclose the reporting person's total AbbVie shareholdings after issuance.
Other notes from the filing: F5 references an AbbVie Savings Program balance (as of Feb 20, 2026); F6 notes the reporting person disclaims beneficial ownership of securities held by her spouse; F7 describes a separate employee stock option grant and its future vesting schedule.
Filing timing: filed two days after the release date — generally within the typical Section 16 reporting window.

Context

These were award releases (transaction code A) — not open‑market purchases or sales — and no cash was exchanged on the reporting date. The awards reflect performance-vesting criteria that were certified by the Compensation Committee; they will be issued on the specified future date.
For retail investors, receipt of performance-based awards documents executive compensation and achieved targets but is not an immediate bullish/bearish signal (it does not represent a purchase funded by the insider).

Insider Transaction Report

Form 4

Period: 2026-02-18

AbbVie Inc.ABBV

SALEKI-GERHARDT AZITA

EVP, CHIEF OPERATIONS OFFICER

Transactions

Award
Common Stock, $0.01 par value
[F1]
2026-02-18+17,041→ 194,333 total
Award
Common Stock, $0.01 par value
[F2]
2026-02-18+6,058→ 200,391 total
Award
Common Stock, $0.01 par value
[F3]
2026-02-18+7,074→ 207,465 total
Award
Common Stock, $0.01 par value
[F4]
2026-02-18+6,638→ 214,103 total
Award
Option (Right to Buy)
[F7]
2026-02-18+20,312→ 20,312 total
Exercise: $230.04Exp: 2036-02-17→ Common Stock (20,312 underlying)

Holdings

Common Stock, $0.01 par value
[F5]
(indirect: By Trust)
2,706
Common Stock, $0.01 par value
[F6]
(indirect: By Spouse)
3,873

Footnotes (7)

[F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
[F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
[F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
[F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
[F5]Balance in AbbVie Savings program as of February 20, 2026. Balance includes shares acquired pursuant to a dividend reinvestment feature.
[F6]The reporting person disclaims beneficial ownership of all securities held by her spouse.
[F7]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,771 on February 18, 2027, 6,771 on February 18, 2028, and 6,770 on February 18, 2029.

Signature

/s/ T.O. Odutayo, Attorney-in-Fact for Azita Saleki-Gerhardt|2026-02-20

Documents

1 file

4
form4-02202026_060209.xmlPrimary